Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and Rituximab for High Risk CLL
NCT00436904Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2004
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, rituximab in chronic lymphocytic leukemia (CLL), sponsored by Mayo Clinic. Started Dec 2004; status: completed.
02
Drugs
alemtuzumabrituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00436904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436904.